MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Fulcrum Therapeutics, Inc. (NASDAQ: FULC)*
Organization & Developments: Fulcrum Therapeutics
Parents
Fulcrum Therapeutics, Inc. (NASDAQ: FULC)*
Children
*The company's development focus is on gene expression to treat the root cause of genetically defined diseases.
2016: Fulcrum, which is developing therapies for Fragile X syndrome and a form of muscular dystrophy, was launched earlier this year with $55 million in financing from Third Rock Ventures LLC, a founding investor in Editas Medicine.
2021: Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point
2021: Our First Look At Fulcrum Therapeutics
2023: An Updated View On Fulcrum Therapeutics (NASDAQ:FULC)
2025: Fulcrum Therapeutics Reports Positive Phase 1b Trial Results
2025: Fulcrum: Next Set Of SCD Data Is Crucial For Continued Pipeline Advancement
2026: Fulcrum lays off 85% of staff after dropping asset, leaving 9 employees
Jumps
*Key People: Fulcrum Therapeutics
Finance & Acquisitions: Fulcrum Therapeutics